why choose us

First received: June 05, 2023

Clinical Trial: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Mantle Cell Lymphoma (MCL)

Study Type: INTERVENTIONAL


Official Title: A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (

Brief Summary: TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants.The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR.Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation.Participants who progress during observation may receive retreatment with acalabrutinib

Read more